AG
CRSP icon

Aperio Group’s CRISPR Therapeutics CRSP Stock Holding History

Aperio Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$435K Buy
+2,838
New +$335K ﹤0.01% 2033
2020
Q2 		– Sell
-5,392
Closed -$229K – 2352
2020
Q1 		$229K Buy
5,392
+921
+21% +$47.6K ﹤0.01% 2042
2019
Q4 		$272K Buy
+4,471
New +$244K ﹤0.01% 2099
2019
Q3 		– Sell
-3,247
Closed -$153K – 2415
2019
Q2 		$153K Buy
+3,247
New +$130K ﹤0.01% 2263

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aperio Group's CRSP Position: Q4 2020 in Review

Aperio Group opened a new position in CRISPR Therapeutics (CRSP) in Q4 2020: 2,838 shares worth $435K. The stake represents ﹤0.01% of the portfolio and ranks #2033 among its holdings. This is a return to the name: Aperio Group previously reported a position in CRSP as recently as Q1 2020.

Aperio Group first reported a position in CRSP in Q2 2019 and has held it in 4 quarters since. 412 funds tracked by Wall St. Rank hold CRSP as of Q4 2020.

  • Aperio Group held 2,838 shares of CRISPR Therapeutics worth $435K as of Q4 2020.
  • CRISPR Therapeutics was a new Aperio Group position in Q4 2020.
  • CRISPR Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2033 holding.
  • Aperio Group first reported a position in CRISPR Therapeutics in Q2 2019 and has held it in 4 quarters since.
  • 412 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.